Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weekly carfilzomib combo shows promise for elderly myeloma patients

NCT ID NCT02302495

Completed Disease control Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tested a weekly dose of the drug carfilzomib combined with two standard chemotherapy drugs (melphalan and prednisone) in 32 elderly patients (65 years or older) with newly diagnosed multiple myeloma. The goal was to find the safest effective dose and see how well the combination works at controlling the disease. The study is now complete.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
carfilzomib
What this could lead to
If successful, this could provide a new treatment option for elderly patients with multiple myeloma, improving response rates while reducing side effects.
What could go wrong
This is a small, early-phase study (32 patients) focused on finding the right dose and initial effectiveness. The combination may still cause significant side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

  • CH Francilien

    Corbeil-Essonnes, 91106, France

  • CH Louis Pasteur

    Colmar, 68024, France

  • CH Meaux

    Meaux, 77104, France

  • CHRU, Hôpitaux de Brabois

    Vandœuvre-lès-Nancy, 54511, France

  • CHRU, Hôtel Dieu

    Nantes, 44035, France

  • CHU Henri Mondor

    Créteil, 94010, France

  • CHU Nimes CAREMEAU

    Nîmes, 30029, France

  • CHU de Limoges

    Limoges, 87000, France

  • Centre Hospitalier H. Duffaut

    Avignon, 84902, France

  • Centre Hospitalier Lyon Sud -1

    Pierre-Bénite, 69495, France

  • Centre Hospitalier William Morey

    Chalon-sur-Saône, 71100, France

  • Centre Hospitalier de Chambery

    Chambéry, 73011, France

  • Centre Hospitalier de la côte basque

    Bayonne, 64109, France

  • Centre Jean Bernard

    Le Mans, 72000, France

  • Centre de NICE 2/ Hôpital Archet

    Nice, 06202, France

  • Centre hospitalier départemental La Roche sur Yon

    La Roche-sur-Yon, 85025, France

  • Chru Lille

    Lille, 59037, France

  • Groupe hospitalier Pitié Salpétrière

    Paris, 75651, France

  • Hopital J Monod

    Montivilliers, 76290, France

  • Hématologie Clinique, CHU, Hôpital d'Enfants

    Dijon, 21000, France

  • Hématologie Clinique, Hôpital Robert Debré, CHU Reims

    Reims, 51092, France

  • Hématologie, IUCT oncopole

    Toulouse, 31059, France

  • Hématologie, Institut Paoli Calmette

    Marseille, 13273, France

  • Hôpital E Muller

    Mulhouse, 68100, France

  • Hôpital Haut-Leveque

    Pessac, 33604, France

  • Hôpital Jean Minjoz

    Besançon, 25030, France

  • Hôpital Notre Dame de Bon Secours

    Metz, 57038, France

  • Hôpital St Antoine

    Paris, 75571, France

  • Hôpital St Antoine Béclére

    Clamart, 92140, France

  • Hôpital St Vincent de Paul - GH-ICL

    Lille, 59020, France

  • Institut Bergonie

    Bordeaux, 33076, France

  • Polyclinique Bordeaux Nord Aquitaine

    Bordeaux, 33300, France

  • Unité de Recherche Clinique - CH Perigueux

    Périgueux, 24019, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.